<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>XELJANZ- tofacitinib citrate tablet, film coated </strong><br>U.S. Pharmaceuticals<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use XELJANZ safely and effectively. See full prescribing information for XELJANZ.<br><br>XELJANZ ® (tofacitinib) tablets for oral administration<br>Initial U.S. Approval: 2012</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> AND MALIGNANCY</h1>
<h1 class="Warning">
<span class="Italics">See</span> full prescribing information <span class="Italics">for complete Boxed Warning.</span>
</h1>
<ul class="Disc">
<li><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> leading to hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, including <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> and bacterial, invasive fungal, viral, and other <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>, have occurred in patients receiving XELJANZ. (<a href="#s5.1">5.1</a>)</span></li>
<li><span class="Bold">If a serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develops, interrupt XELJANZ until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is controlled. (<a href="#s5.1">5.1</a>)</span></li>
<li><span class="Bold">Prior to starting XELJANZ, perform a test for latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>; if it is positive, start treatment for <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> prior to starting XELJANZ. (<a href="#s5.1">5.1</a>)</span></li>
<li><span class="Bold">Monitor all patients for active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> during treatment, even if the initial latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> test is negative. (<a href="#s5.1">5.1</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and other malignancies have been observed in patients treated with XELJANZ. Epstein Barr Virus- associated post-transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span> has been observed at an increased rate in renal transplant patients treated with XELJANZ and concomitant immunosuppressive medications. (<a href="#s5.2">5.2</a>)</span></li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> AND MALIGNANCY</h1>
<h1 class="Warning">
<span class="Italics">See</span> full prescribing information <span class="Italics">for complete Boxed Warning.</span>
</h1>
<ul class="Disc">
<li><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> leading to hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, including <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> and bacterial, invasive fungal, viral, and other <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>, have occurred in patients receiving XELJANZ. (<a href="#s5.1">5.1</a>)</span></li>
<li><span class="Bold">If a serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develops, interrupt XELJANZ until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is controlled. (<a href="#s5.1">5.1</a>)</span></li>
<li><span class="Bold">Prior to starting XELJANZ, perform a test for latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>; if it is positive, start treatment for <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> prior to starting XELJANZ. (<a href="#s5.1">5.1</a>)</span></li>
<li><span class="Bold">Monitor all patients for active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> during treatment, even if the initial latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> test is negative. (<a href="#s5.1">5.1</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and other malignancies have been observed in patients treated with XELJANZ. Epstein Barr Virus- associated post-transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span> has been observed at an increased rate in renal transplant patients treated with XELJANZ and concomitant immunosuppressive medications. (<a href="#s5.2">5.2</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul class="Disc">
<li>XELJANZ, an inhibitor of Janus kinases (JAKs), is indicated for the treatment of adult patients with moderately to severely active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).</li>
<li>XELJANZ should not be used in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine. (<a href="#s1.1">1.1</a>)</li>
</ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></span>  (<a href="#section-2">2</a>)</p>
<p class="Highlighta">  The recommended dose of XELJANZ is 5 mg twice daily.  (<a href="#section-2">2</a>)</p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Tablets: 5 mg (<a href="#s3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None (<a href="#s4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> – Do not administer XELJANZ during an active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4018050" conceptname="Localized infection">localized infections</span>. If a serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develops, interrupt XELJANZ until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is controlled. (<a href="#s5.1">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphomas</span> and other malignancies have been reported in patients treated with XELJANZ. (<a href="#s5.2">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforations</span> – Use with caution in patients that may be at increased risk. (<a href="#s5.3">5.3</a>)</li>
<li>Laboratory monitoring –Recommended due to potential changes in <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>, hemoglobin, liver enzymes and lipids. (<a href="#s5.4">5.4</a>)</li>
<li>Immunizations –Live vaccines should not be given concurrently with XELJANZ. (<a href="#s5.5">5. 5</a>)</li>
<li>Severe hepatic impairment–Not recommended (<a href="#s5.6">5.6</a>)</li>
</ul></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">The most commonly reported adverse reactions during the first 3 months in controlled clinical trials (occurring in greater than or equal to 2% of patients treated with XELJANZ monotherapy or in combination with DMARDs) were <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>. (<a href="#s6.1">6.1</a>)<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Potent inhibitors of Cytochrome P450 3A4 (CYP3A4) (e.g., ketoconazole): Reduce dose to 5 mg once daily. (<a href="#s2.1">2.1</a>)</li>
<li>One or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole): Reduce dose to 5 mg once daily. (<a href="#s2.1">2.1</a>)</li>
<li>Potent CYP inducers (e.g., rifampin): May result in loss of or reduced clinical response. (<a href="#s2.2">2.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>: Reduce dose to 5 mg once daily. (<a href="#s8.6">8.6</a>, <a href="#s8.7">8.7</a>) </p></div>
<div>
<div><div></div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 11/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> AND MALIGNANCY</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 General Considerations for Administration</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dosage Modifications</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Malignancy and <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">Lymphoproliferative Disorder</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforations</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Laboratory Parameters</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Vaccinations</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Potent CYP3A4 Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Moderate CYP3A4 and Potent CYP2C19 Inhibitors</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Potent CYP3A4 Inducers</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Immunosuppressive Drugs</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> AND MALIGNANCY</span></h1>
<p class="First"><span class="Bold">SERIOUS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></span></p>
<p><span class="Bold">Patients treated with XELJANZ are at increased risk for developing serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that may lead to hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> <span class="Italics">[see <a href="#s5.1">Warnings and Precautions (5.1)</a> and <a href="#s6.1">Adverse Reactions (6.1)</a>]</span>. Most patients who developed these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were taking concomitant immunosuppressants such as methotrexate or corticosteroids.</span></p>
<p><span class="Bold">If a serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develops, interrupt XELJANZ until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is controlled.</span></p>
<p><span class="Bold">Reported <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> include:</span></p>
<ul class="Disc">
<li><span class="Bold">Active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> before XELJANZ use and during therapy. Treatment for latent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should be initiated prior to XELJANZ use.</span></li>
<li><span class="Bold">Invasive <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>, including <span class="product-label-link" type="condition" conceptid="440035" conceptname="Cryptococcosis">cryptococcosis</span> and <span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">pneumocystosis</span>. Patients with invasive <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> may present with disseminated, rather than localized, disease.</span></li>
<li><span class="Bold">Bacterial, viral, and other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to opportunistic pathogens.</span></li>
</ul>
<p><span class="Bold">The risks and benefits of treatment with XELJANZ should be carefully considered prior to initiating therapy in patients with chronic or recurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</span></p>
<p><span class="Bold">Patients should be closely monitored for the development of signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> during and after treatment with XELJANZ, including the possible development of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> in patients who tested negative for latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> prior to initiating therapy <span class="Italics">[see <a href="#s5.1">Warnings and Precautions (5.1)</a>]</span>.</span></p>
<p><span class="Bold">MALIGNANCIES</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and other malignancies have been observed in patients treated with XELJANZ. Epstein Barr Virus- associated post-transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span> has been observed at an increased rate in renal transplant patients treated with XELJANZ and concomitant immunosuppressive medications <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></h2>
<ul class="Disc">
<li>XELJANZ (tofacitinib) is indicated for the treatment of adult patients with moderately to severely active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).</li>
<li>XELJANZ should not be used in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">XELJANZ is given orally with or without food.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></h2>
<p class="First">XELJANZ may be used as monotherapy or in combination with methotrexate or other nonbiologic disease modifying antirheumatic drugs (DMARDs). The recommended dose of XELJANZ is 5 mg twice daily.</p>
<ul class="Square">
<li>Dose interruption is recommended for management of <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> <span class="Italics">[see <a href="#s2.3">Dosage and Administration (2.3)</a>, <a href="#s5.4">Warnings and Precautions (5.4)</a>, and <a href="#s6.1">Adverse Reactions (6.1)</a>]</span>.</li>
<li>XELJANZ dosage should be reduced to 5 mg once daily in patients:<ul class="Disc">
<li>with moderate or severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span></li>
<li>with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span></li>
<li>receiving potent inhibitors of Cytochrome P450 3A4 (CYP3A4) (e.g., ketoconazole)</li>
<li>receiving one or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole).</li>
</ul>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 General Considerations for Administration</h2>
<ul class="Square">
<li>XELJANZ should not be used in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</li>
<li>It is recommended that XELJANZ not be initiated in patients with a lymphocyte count less than 500 cells/mm<span class="Sup">3</span>, an absolute neutrophil count (ANC) less than 1000 cells/mm<span class="Sup">3</span>, or who have hemoglobin levels less than 9 g/dL.</li>
<li>Coadministration of XELJANZ with potent inducers of CYP3A4 (e.g., rifampin) may result in loss of or reduced clinical response to XELJANZ.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dosage Modifications</h2>
<p class="First">XELJANZ treatment should be interrupted if a patient develops a serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is controlled.</p>
<table width="100%">
<caption><span>Table 1: Dose Adjustments for <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span></span></caption>
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="70%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="2">Low Lymphocyte Count <span class="Italics">[see <a href="#s5.4">Warnings and Precautions (5.4)</a>]</span>
</th></tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Lab Value<br>(cells/mm<span class="Sup">3</span>)</th>
<th class="Rrule" align="center">Recommendation</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Lymphocyte count greater than or equal to 500</td>
<td class="Rrule" align="left">Maintain dose</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Lymphocyte count less than 500</td>
<td class="Rrule" align="left">Discontinue XELJANZ</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">(Confirmed by repeat testing)</td>
<td class="Rrule" align="left"></td>
</tr>
</tbody>
</table>
<table width="100%">
<caption><span>Table 2: Dose Adjustments for <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></caption>
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="70%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="2">Low ANC <span class="Italics">[see <a href="#s5.4">Warnings and Precautions (5.4)</a>]</span>
</th></tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Lab Value<br>(cells/mm<span class="Sup">3</span>)</th>
<th class="Rrule" align="center">Recommendation</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">ANC greater than 1000</td>
<td class="Rrule" align="left">Maintain dose</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">ANC 500–1000</td>
<td class="Rrule" align="left">For persistent decreases in this range, interrupt dosing until ANC is greater than 1000</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left">When ANC is greater than 1000, resume XELJANZ 5 mg twice daily</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">ANC less than 500</td>
<td class="Rrule" align="left">Discontinue XELJANZ</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">(Confirmed by repeat testing)</td>
<td class="Rrule" align="left"></td>
</tr>
</tbody>
</table>
<table width="100%">
<caption><span>Table 3: Dose Adjustments for <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></span></caption>
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="70%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="2">Low Hemoglobin Value <span class="Italics">[see <a href="#s5.4">Warnings and Precautions (5.4)</a>]</span>
</th></tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Lab Value<br>(g/dL)</th>
<th class="Rrule" align="center">Recommendation</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Less than or equal to 2 g/dL decrease and greater than or equal to 9.0 g/dL</td>
<td class="Rrule" align="left">Maintain dose</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Greater than 2 g/dL decrease or less than 8.0 g/dL</td>
<td class="Rrule" align="left">Interrupt the administration of XELJANZ until hemoglobin values have normalized</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">(Confirmed by repeat testing)</td>
<td class="Rrule" align="left"></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">XELJANZ is provided as 5 mg tofacitinib (equivalent to 8 mg tofacitinib citrate) tablets: White, round, immediate-release film-coated tablets, debossed with "Pfizer" on one side, and "JKI 5" on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Serious and sometimes fatal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients receiving XELJANZ. The most common serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> reported with XELJANZ included <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> <span class="Italics">[see <a href="#s6.1">Adverse Reactions (6.1)</a>]</span>. Among <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>, <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> and other <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infections</span>, cryptococcus, <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>, <span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">pneumocystosis</span>, multidermatomal <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, cytomegalovirus, and BK virus were reported with XELJANZ. Some patients have presented with disseminated rather than localized disease, and were often taking concomitant immunomodulating agents such as methotrexate or corticosteroids.</p>
<p>Other serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that were not reported in clinical studies may also occur (e.g., <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span>, <span class="product-label-link" type="condition" conceptid="437217" conceptname="Coccidioidomycosis">coccidioidomycosis</span>, and <span class="product-label-link" type="condition" conceptid="438059" conceptname="Listeriosis">listeriosis</span>).</p>
<p>XELJANZ should not be initiated in patients with an active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4018050" conceptname="Localized infection">localized infections</span>. The risks and benefits of treatment should be considered prior to initiating XELJANZ in patients:</p>
<ul class="Disc">
<li>with chronic or recurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></li>
<li>who have been exposed to <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></li>
<li>with a history of a serious or an <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infection</span></li>
<li>who have resided or traveled in areas of endemic <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or endemic mycoses; or</li>
<li>with underlying conditions that may predispose them to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
</ul>
<p>Patients should be closely monitored for the development of signs and symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> during and after treatment with XELJANZ. XELJANZ should be interrupted if a patient develops a serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, an <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infection</span>, or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>. A patient who develops a new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> during treatment with XELJANZ should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be initiated, and the patient should be closely monitored.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></span></p>
<p>Patients should be evaluated and tested for latent or active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> prior to administration of XELJANZ.</p>
<p>Anti-<span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> therapy should also be considered prior to administration of XELJANZ in patients with a past history of latent or active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> but who have risk factors for <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Consultation with a physician with expertise in the treatment of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> is recommended to aid in the decision about whether initiating anti-<span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> therapy is appropriate for an individual patient.</p>
<p>Patients should be closely monitored for the development of signs and symptoms of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, including patients who tested negative for latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> prior to initiating therapy.</p>
<p>Patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> should be treated with standard antimycobacterial therapy before administering XELJANZ.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.2"></a><p></p>
<p class="First"><span class="Bold">Viral Reactivation</span></p>
<p>Viral reactivation, including cases of herpes virus reactivation (e.g., <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>), were observed in clinical studies with XELJANZ. The impact of XELJANZ on chronic <span class="product-label-link" type="condition" conceptid="4291005" conceptname="Viral hepatitis">viral hepatitis</span> reactivation is unknown. Patients who screened positive for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C were excluded from clinical trials.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Malignancy and <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">Lymphoproliferative Disorder</span></h2>
<p class="First">Consider the risks and benefits of XELJANZ treatment prior to initiating therapy in patients with a known malignancy other than a successfully treated non-<span class="product-label-link" type="condition" conceptid="4049499" conceptname="Malignant melanoma">melanoma skin</span> cancer (NMSC) or when considering continuing XELJANZ in patients who develop a malignancy. Malignancies were observed in clinical studies of XELJANZ <span class="Italics">[see <a href="#s6.1">Adverse Reactions (6.1)</a>].</span></p>
<p>In the seven controlled <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> clinical studies, 11 solid cancers and one <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> were diagnosed in 3328 patients receiving XELJANZ with or without DMARD, compared to 0 solid cancers and 0 <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> in 809 patients in the placebo with or without DMARD group during the first 12 months of exposure. <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphomas</span> and solid cancers have also been observed in the long-term extension studies in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients treated with XELJANZ.</p>
<p>In Phase 2B, controlled dose-ranging trials in <span class="Italics">de-novo</span> renal transplant patients, all of whom received induction therapy with basiliximab, high dose corticosteroids, and mycophenolic acid products, Epstein Barr Virus-associated post-transplant <span class="product-label-link" type="condition" conceptid="4079147" conceptname="Lymphoproliferative disorder">lymphoproliferative disorder</span> was observed in 5 out of 218 patients treated with XELJANZ (2.3%) compared to 0 out of 111 patients treated with cyclosporine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">Gastrointestinal Perforations</span></h2>
<p class="First">Events of <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> have been reported in clinical studies with XELJANZ in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients, although the role of JAK inhibition in these events is not known.</p>
<p>XELJANZ should be used with caution in patients who may be at increased risk for <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> (e.g., patients with a history of <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>). Patients presenting with new onset abdominal symptoms should be evaluated promptly for early identification of <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> <span class="Italics">[see <a href="#s6.1">Adverse Reactions (6.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Laboratory Parameters</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">Lymphocytes</span></span></p>
<p>Treatment with XELJANZ was associated with initial <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span> at one month of exposure followed by a gradual decrease in mean lymphocyte counts below the baseline of approximately 10% during 12 months of therapy. Lymphocyte counts less than 500 cells/mm<span class="Sup">3</span> were associated with an increased incidence of treated and serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>Avoid initiation of XELJANZ treatment in patients with a low lymphocyte count (i.e., less than 500 cells/mm<span class="Sup">3</span>). In patients who develop a confirmed absolute lymphocyte count less than 500 cells/mm<span class="Sup">3</span> treatment with XELJANZ is not recommended.</p>
<p>Monitor lymphocyte counts at baseline and every 3 months thereafter. For recommended modifications based on lymphocyte counts <span class="Italics">see <a href="#s2.3">Dosage and Administration (2.3)</a></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span></span></p>
<p>Treatment with XELJANZ was associated with an increased incidence of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (less than 2000 cells/mm<span class="Sup">3</span>) compared to placebo.</p>
<p>Avoid initiation of XELJANZ treatment in patients with a low neutrophil count (i.e., ANC less than 1000 cells/mm<span class="Sup">3</span>). For patients who develop a persistent ANC of 500–1000 cells/mm<span class="Sup">3</span>, interrupt XELJANZ dosing until ANC is greater than or equal to 1000 cells/mm<span class="Sup">3</span>. In patients who develop an ANC less than 500 cells/mm<span class="Sup">3</span>, treatment with XELJANZ is not recommended.</p>
<p>Monitor neutrophil counts at baseline and after 4–8 weeks of treatment and every 3 months thereafter. For recommended modifications based on ANC results <span class="Italics">see <a href="#s2.3">Dosage and Administration (2.3)</a></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4.3"></a><p></p>
<p class="First"><span class="Bold">Hemoglobin</span></p>
<p>Avoid initiation of XELJANZ treatment in patients with a low hemoglobin level (i.e. less than 9 g/dL). Treatment with XELJANZ should be interrupted in patients who develop hemoglobin levels less than 8 g/dL or whose hemoglobin level drops greater than 2 g/dL on treatment.</p>
<p>Monitor hemoglobin at baseline and after 4–8 weeks of treatment and every 3 months thereafter. For recommended modifications based on hemoglobin results <span class="Italics">see <a href="#s2.3">Dosage and Administration (2.3)</a></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4.4"></a><p></p>
<p class="First"><span class="Bold">Liver Enzymes</span></p>
<p>Treatment with XELJANZ was associated with an increased incidence of liver enzyme elevation compared to placebo. Most of these abnormalities occurred in studies with background DMARD (primarily methotrexate) therapy.</p>
<p>Routine monitoring of liver tests and prompt investigation of the causes of liver enzyme elevations is recommended to identify potential cases of drug-induced <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. If drug-induced <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is suspected, the administration of XELJANZ should be interrupted until this diagnosis has been excluded.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4.5"></a><p></p>
<p class="First"><span class="Bold">Lipids</span></p>
<p>Treatment with XELJANZ was associated with increases in lipid parameters including total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, low-density lipoprotein (LDL) <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and high-density lipoprotein (HDL) <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. Maximum effects were generally observed within 6 weeks. The effect of these lipid parameter elevations on cardiovascular morbidity and mortality has not been determined.</p>
<p>Assessment of lipid parameters should be performed approximately 4–8 weeks following initiation of XELJANZ therapy.</p>
<p>Manage patients according to clinical guidelines [e.g., National <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Educational Program (NCEP)] for the management of <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Vaccinations</h2>
<p class="First">No data are available on the response to vaccination or on the secondary transmission of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> by live vaccines to patients receiving XELJANZ. Live vaccines should not be given concurrently with XELJANZ.</p>
<p>Update immunizations in agreement with current immunization guidelines prior to initiating XELJANZ therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Treatment with XELJANZ is not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#s6.1">Adverse Reactions (6.1)</a> and <a href="#s8.6">Use in Specific Populations (8.6)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not predict the rates observed in a broader patient population in clinical practice.</p>
<p>The following data includes two Phase 2 and five Phase 3 double-blind, controlled, multicenter trials. In these trials, patients were randomized to doses of XELJANZ 5 mg twice daily (292 patients) and 10 mg twice daily (306 patients) monotherapy, XELJANZ 5 mg twice daily (1044 patients) and 10 mg twice daily (1043 patients) in combination with DMARDs (including methotrexate) and placebo (809 patients). All seven protocols included provisions for patients taking placebo to receive treatment with XELJANZ at Month 3 or Month 6 either by patient response (based on uncontrolled disease activity) or by design, so that adverse events cannot always be unambiguously attributed to a given treatment. Therefore some analyses that follow include patients who changed treatment by design or by patient response from placebo to XELJANZ in both the placebo and XELJANZ group of a given interval. Comparisons between placebo and XELJANZ were based on the first 3 months of exposure, and comparisons between XELJANZ 5 mg twice daily and XELJANZ 10 mg twice daily were based on the first 12 months of exposure.</p>
<p>The long-term safety population includes all patients who participated in a double-blind, controlled trial (including earlier development phase studies) and then participated in one of two long-term safety studies. The design of the long-term safety studies allowed for modification of XELJANZ doses according to clinical judgment. This limits the interpretation of the long-term safety data with respect to dose.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience</h2>
<p class="First">The most common serious adverse reactions were serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> <span class="Italics">[see <a href="#s5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
<p>The proportion of patients who discontinued treatment due to any adverse reaction during the 0 to 3 months exposure in the double-blind, placebo-controlled trials was 4% for patients taking XELJANZ and 3% for placebo-treated patients.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold">Overall <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></p>
<p>In the seven controlled trials, during the 0 to 3 months exposure, the overall frequency of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> was 20% and 22% in the 5 mg twice daily and 10 mg twice daily groups, respectively, and 18% in the placebo group.</p>
<p>The most commonly reported <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with XELJANZ were <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> (4%, 3%, and 2% of patients, respectively).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></p>
<p>In the seven controlled trials, during the 0 to 3 months exposure, serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were reported in 1 patient (0.5 events per 100 patient-years) who received placebo and 11 patients (1.7 events per 100 patient-years) who received XELJANZ 5 mg or 10 mg twice daily. The rate difference between treatment groups (and the corresponding 95% confidence interval) was 1.1 (-0.4, 2.5) events per 100 patient-years for the combined 5 mg twice daily and 10 mg twice daily XELJANZ group minus placebo.</p>
<p>In the seven controlled trials, during the 0 to 12 months exposure, serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were reported in 34 patients (2.7 events per 100 patient-years) who received 5 mg twice daily of XELJANZ and 33 patients (2.7 events per 100 patient-years) who received 10 mg twice daily of XELJANZ. The rate difference between XELJANZ doses (and the corresponding 95% confidence interval) was -0.1 (-1.3, 1.2) events per 100 patient-years for 10 mg twice daily XELJANZ minus 5 mg twice daily XELJANZ.</p>
<p>The most common serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> included <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> <span class="Italics">[see <a href="#s5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></span></p>
<p>In the seven controlled trials, during the 0 to 3 months exposure, <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> was not reported in patients who received placebo, 5 mg twice daily of XELJANZ, or 10 mg twice daily of XELJANZ.</p>
<p>In the seven controlled trials, during the 0 to 12 months exposure, <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> was reported in 0 patients who received 5 mg twice daily of XELJANZ and 6 patients (0.5 events per 100 patient-years) who received 10 mg twice daily of XELJANZ. The rate difference between XELJANZ doses (and the corresponding 95% confidence interval) was 0.5 (0.1, 0.9) events per 100 patient-years for 10 mg twice daily XELJANZ minus 5 mg twice daily XELJANZ.</p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="4112387" conceptname="Disseminated tuberculosis">disseminated tuberculosis</span> were also reported. The median XELJANZ exposure prior to diagnosis of <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> was 10 months (range from 152 to 960 days) [<span class="Italics">see <a href="#s5.1">Warnings and Precautions (5.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">Opportunistic Infections</span> (excluding <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>)</span></p>
<p>In the seven controlled trials, during the 0 to 3 months exposure, <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> were not reported in patients who received placebo, 5 mg twice daily of XELJANZ, or 10 mg twice daily of XELJANZ.</p>
<p>In the seven controlled trials, during the 0 to 12 months exposure, <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> were reported in 4 patients (0.3 events per 100 patient-years) who received 5 mg twice daily of XELJANZ and 4 patients (0.3 events per 100 patient-years) who received 10 mg twice daily of XELJANZ. The rate difference between XELJANZ doses (and the corresponding 95% confidence interval) was 0 (-0.5, 0.5) events per 100 patient-years for 10 mg twice daily XELJANZ minus 5 mg twice daily XELJANZ.</p>
<p>The median XELJANZ exposure prior to diagnosis of an <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infection</span> was 8 months (range from 41 to 698 days) <span class="Italics">[see <a href="#s5.1">Warnings and Precautions (5.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Bold">Malignancy</span></p>
<p>In the seven controlled trials, during the 0 to 3 months exposure, malignancies excluding NMSC were reported in 0 patients who received placebo and 2 patients (0.3 events per 100 patient-years) who received either XELJANZ 5 mg or 10 mg twice daily. The rate difference between treatment groups (and the corresponding 95% confidence interval) was 0.3 (-0.1, 0.7) events per 100 patient-years for the combined 5 mg and 10 mg twice daily XELJANZ group minus placebo.</p>
<p>In the seven controlled trials, during the 0 to 12 months exposure, malignancies excluding NMSC were reported in 5 patients (0.4 events per 100 patient-years) who received 5 mg twice daily of XELJANZ and 7 patients (0.6 events per 100 patient-years) who received 10 mg twice daily of XELJANZ. The rate difference between XELJANZ doses (and the corresponding 95% confidence interval) was 0.2 (-0.4, 0.7) events per 100 patient-years for 10 mg twice daily XELJANZ minus 5 mg twice daily XELJANZ. One of these malignancies was a case of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> that occurred during the 0 to 12 month period in a patient treated with XELJANZ 10 mg twice daily.</p>
<p>The most common types of malignancy, including malignancies observed during the long-term extension, were lung and breast cancer, followed by gastric, colorectal, renal cell, prostate cancer, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, and malignant melanoma <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-6.1.6"></a><p></p>
<p class="First"><span class="Bold Italics">Laboratory Tests</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.6.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">Lymphocytes</span></span></p>
<p>In the controlled clinical trials, confirmed decreases in lymphocyte counts below 500 cells/mm<span class="Sup">3</span> occurred in 0.04% of patients for the 5 mg twice daily and 10 mg twice daily XELJANZ groups combined during the first 3 months of exposure.</p>
<p>Confirmed lymphocyte counts less than 500 cells/mm<span class="Sup">3</span> were associated with an increased incidence of treated and serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> <span class="Italics">[see <a href="#s5.4">Warnings and Precautions (5.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.6.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span></span></p>
<p>In the controlled clinical trials, confirmed decreases in ANC below 1000 cells/mm<span class="Sup">3</span> occurred in 0.07% of patients for the 5 mg twice daily and 10 mg twice daily XELJANZ groups combined during the first 3 months of exposure.</p>
<p>There were no confirmed decreases in ANC below 500 cells/mm<span class="Sup">3</span> observed in any treatment group.</p>
<p>There was no clear relationship between <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and the occurrence of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>In the long-term safety population, the pattern and incidence of confirmed decreases in ANC remained consistent with what was seen in the controlled clinical trials <span class="Italics">[see <a href="#s5.4">Warnings and Precautions (5.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.6.3"></a><p></p>
<p class="First"><span class="Bold">Liver Enzyme Tests</span></p>
<p>Confirmed increases in liver enzymes greater than 3 times the upper limit of normal (3× ULN) were observed in patients treated with XELJANZ. In patients experiencing liver enzyme elevation, modification of treatment regimen, such as reduction in the dose of concomitant DMARD, interruption of XELJANZ, or reduction in XELJANZ dose, resulted in decrease or normalization of liver enzymes.</p>
<p>In the controlled monotherapy trials (0–3 months), no differences in the incidence of ALT or AST elevations were observed between the placebo, and XELJANZ 5 mg, and 10 mg twice daily groups.</p>
<p>In the controlled background DMARD trials (0–3 months), ALT elevations greater than 3× ULN were observed in 1.0%, 1.3% and 1.2% of patients receiving placebo, 5 mg, and 10 mg twice daily, respectively. In these trials, AST elevations greater than 3× ULN were observed in 0.6%, 0.5% and 0.4% of patients receiving placebo, 5 mg, and 10 mg twice daily, respectively.</p>
<p>One case of drug-induced <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> was reported in a patient treated with XELJANZ 10 mg twice daily for approximately 2.5 months. The patient developed symptomatic elevations of AST and ALT greater than 3× ULN and bilirubin elevations greater than 2× ULN, which required hospitalizations and a liver biopsy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.6.4"></a><p></p>
<p class="First"><span class="Bold">Lipids</span></p>
<p>In the controlled clinical trials, dose-related elevations in lipid parameters (total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, triglycerides) were observed at one month of exposure and remained stable thereafter. Changes in lipid parameters during the first 3 months of exposure in the controlled clinical trials are summarized below:</p>
<ul class="Disc">
<li>Mean LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> increased by 15% in the XELJANZ 5 mg twice daily arm and 19% in the XELJANZ 10 mg twice daily arm.</li>
<li>Mean HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> increased by 10% in the XELJANZ 5 mg twice daily arm and 12% in the XELJANZ 10 mg twice daily arm.</li>
<li>Mean LDL/HDL ratios were essentially unchanged in XELJANZ-treated patients.</li>
</ul>
<p>In a controlled clinical trial, elevations in LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and ApoB decreased to pretreatment levels in response to statin therapy.</p>
<p>In the long-term safety population, elevations in lipid parameters remained consistent with what was seen in the controlled clinical trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.6.5"></a><p></p>
<p class="First"><span class="Bold">Serum Creatinine</span></p>
<p>In the controlled clinical trials, dose-related elevations in serum creatinine were observed with XELJANZ treatment. The mean increase in serum creatinine was &lt;0.1 mg/dL in the 12-month pooled safety analysis; however with increasing duration of exposure in the long-term extensions, up to 2% of patients were discontinued from XELJANZ treatment due to the protocol-specified discontinuation criterion of an increase in creatinine by more than 50% of baseline. The clinical significance of the observed serum creatinine elevations is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.7"></a><p></p>
<p class="First"><span class="Bold">Other Adverse Reactions</span></p>
<p>Adverse reactions occurring in 2% or more of patients on 5 mg twice daily or 10 mg twice daily XELJANZ and at least 1% greater than that observed in patients on placebo with or without DMARD are summarized in Table 4.</p>
<table width="100%">
<caption><span>Table 4: Adverse Reactions Occurring in at Least 2% or More of Patients on 5 or 10 mg Twice Daily XELJANZ With or Without DMARD (0–3 months) and at Least 1% Greater Than That Observed in Patients on Placebo</span></caption>
<col align="left" valign="middle" width="30%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="30%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">XELJANZ<br>5 mg Twice Daily</th>
<th class="Rrule" align="center">XELJANZ<br>10 mg Twice Daily</th>
<th class="Rrule" align="center">Placebo</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Preferred Term</th>
<th class="Rrule" align="center">N = 1336<br>(%)</th>
<th class="Rrule" align="center">N = 1349<br>(%)</th>
<th class="Rrule" align="center">N = 809<br>(%)</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="4" valign="top">N reflects randomized and treated patients from the seven clinical trials</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">4.0</td>
<td class="Rrule" align="center">2.9</td>
<td class="Rrule" align="center">2.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Rrule" align="center">3.8</td>
<td class="Rrule" align="center">2.8</td>
<td class="Rrule" align="center">2.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Rrule" align="center">4.5</td>
<td class="Rrule" align="center">3.8</td>
<td class="Rrule" align="center">3.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">4.3</td>
<td class="Rrule" align="center">3.4</td>
<td class="Rrule" align="center">2.1</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule" align="center">1.6</td>
<td class="Rrule" align="center">2.3</td>
<td class="Rrule" align="center">1.1</td>
</tr>
</tbody>
</table>
<p>Other adverse reactions occurring in controlled and open-label extension studies included:</p>
<p><span class="Bold">Blood and lymphatic system disorders:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span><br><span class="Bold">Metabolism and nutrition disorders:</span> <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span><br><span class="Bold">Psychiatric disorders:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span><br><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4220211" conceptname="Congestion of nasal sinus">sinus congestion</span><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span><br><span class="Bold">Hepatobiliary disorders:</span> <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">Hepatic steatosis</span><br><span class="Bold">Skin and subcutaneous tissue disorders:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span><br><span class="Bold">Musculoskeletal, connective tissue and <span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">bone disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendonitis</span>, <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span><br><span class="Bold">General disorders and administration site conditions:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Potent CYP3A4 Inhibitors</h2>
<p class="First">Tofacitinib exposure is increased when XELJANZ is coadministered with potent inhibitors of cytochrome P450 (CYP) 3A4 (e.g., ketoconazole) <span class="Italics">[see <a href="#s2.1">Dosage and Administration (2.1)</a> and <a href="#fig3">Figure 3</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Moderate CYP3A4 and Potent CYP2C19 Inhibitors</h2>
<p class="First">Tofacitinib exposure is increased when XELJANZ is coadministered with medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole) <span class="Italics">[see <a href="#s2.1">Dosage and Administration (2.1)</a> and <a href="#fig3">Figure 3</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Potent CYP3A4 Inducers</h2>
<p class="First">Tofacitinib exposure is decreased when XELJANZ is coadministered with potent CYP3A4 inducers (e.g., rifampin) <span class="Italics">[see <a href="#s2.1">Dosage and Administration (2.1)</a> and <a href="#fig3">Figure 3</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Immunosuppressive Drugs</h2>
<p class="First">There is a risk of added <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> when XELJANZ is coadministered with potent immunosuppressive drugs (e.g., azathioprine, tacrolimus, cyclosporine). Combined use of multiple-dose XELJANZ with potent immunosuppressives has not been studied in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Teratogenic effects:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category C.</span> There are no adequate and well-controlled studies in pregnant women. XELJANZ should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Tofacitinib has been shown to be fetocidal and teratogenic in rats and rabbits when given at exposures 146 times and 13 times, respectively, the maximum recommended human dose (MRHD).</p>
<p>In a rat embryofetal developmental study, tofacitinib was teratogenic at exposure levels approximately 146 times the MRHD (on an AUC basis at oral doses of 100 mg/kg/day). Teratogenic effects consisted of external and soft tissue malformations of <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">anasarca</span> and membranous <span class="product-label-link" type="condition" conceptid="434462" conceptname="Ventricular septal defect">ventricular septal defects</span>, respectively, and skeletal malformations or variations (absent cervical arch; bent femur, fibula, humerus, radius, scapula, tibia, and ulna; sternoschisis; absent rib; misshapen femur; branched rib; fused rib; fused sternebra; and hemicentric thoracic centrum). In addition, there was an increase in post-implantation loss, consisting of early and late resorptions, resulting in a reduced number of viable fetuses. Mean fetal body weight was reduced. No developmental toxicity was observed in rats at exposure levels approximately 58 times the MRHD (on an AUC basis at oral doses of 30 mg/kg/day). In the rabbit embryofetal developmental study, tofacitinib was teratogenic at exposure levels approximately 13 times the MRHD (on an AUC basis at oral doses of 30 mg/kg/day) in the absence of signs of maternal toxicity. Teratogenic effects included thoracogastroschisis, <span class="product-label-link" type="condition" conceptid="4077297" conceptname="Congenital omphalocele">omphalocele</span>, membranous <span class="product-label-link" type="condition" conceptid="434462" conceptname="Ventricular septal defect">ventricular septal defects</span>, and cranial/skeletal malformations (microstomia, <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>), mid-line and tail defects. In addition, there was an increase in post-implantation loss associated with late resorptions. No developmental toxicity was observed in rabbits at exposure levels approximately 3 times the MRHD (on an AUC basis at oral doses of 10 mg/kg/day).</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">Nonteratogenic effects:</span></p>
<p>In a peri- and postnatal rat study, there were reductions in live litter size, postnatal survival, and pup body weights at exposure levels approximately 73 times the MRHD (on an AUC basis at oral doses of 50 mg/kg/day). There was no effect on behavioral and learning assessments, sexual maturation or the ability of the F1 generation rats to mate and produce viable F2 generation fetuses in rats at exposure levels approximately 17 times the MRHD (on an AUC basis at oral doses of 10 mg/kg/day).</p>
<p>Pregnancy Registry: To monitor the outcomes of pregnant women exposed to XELJANZ, a pregnancy registry has been established. Physicians are encouraged to register patients and pregnant women are encouraged to register themselves by calling 1-877-311-8972.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Tofacitinib was secreted in milk of lactating rats. It is not known whether tofacitinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from tofacitinib, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug for the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of XELJANZ in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 3315 patients who enrolled in Studies I to V, a total of 505 <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients were 65 years of age and older, including 71 patients 75 years and older. The frequency of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> among XELJANZ-treated subjects 65 years of age and older was higher than among those under the age of 65. As there is a higher incidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in the elderly population in general, caution should be used when treating the elderly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dose adjustment is required in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. XELJANZ dose should be reduced to 5 mg once daily in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The safety and efficacy of XELJANZ have not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> or in patients with positive <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus serology <span class="Italics">[see <a href="#s2.1">Dosage and Administration (2.1)</a> and <a href="#s5.6">Warnings and Precautions (5.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dose adjustment is required in patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. XELJANZ dose should be reduced to 5 mg once daily in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#s2.1">Dosage and Administration (2.1)</a>]</span>. In clinical trials, XELJANZ was not evaluated in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients with baseline creatinine clearance values (estimated by the Cockroft-Gault equation) less than 40 mL/min.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<p class="First"><span class="Bold">Signs, Symptoms, and Laboratory Findings of Acute Overdosage in Humans</span></p>
<p>There is no experience with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of XELJANZ.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<p class="First"><span class="Bold">Treatment or Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></span></p>
<p>Pharmacokinetic data up to and including a single dose of 100 mg in healthy volunteers indicate that more than 95% of the administered dose is expected to be eliminated within 24 hours.</p>
<p>There is no specific antidote for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with XELJANZ. In case of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, it is recommended that the patient be monitored for signs and symptoms of adverse reactions. Patients who develop adverse reactions should receive appropriate treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">XELJANZ is the citrate salt of tofacitinib, a JAK inhibitor.</p>
<p>Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitrile, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) . It is freely soluble in water.</p>
<p>Tofacitinib citrate has a molecular weight of 504.5 Daltons (or 312.4 Daltons as the tofacitinib free base) and a molecular formula of C<span class="Sub">16</span>H<span class="Sub">20</span>N<span class="Sub">6</span>O•C<span class="Sub">6</span>H<span class="Sub">8</span>O<span class="Sub">7</span>. The chemical structure of tofacitinib citrate is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13&amp;name=xeljanz-01.jpg"></div>
<p>XELJANZ is supplied for oral administration as 5 mg tofacitinib (equivalent to 8 mg tofacitinib citrate) white round, immediate-release film-coated tablet. Each tablet of XELJANZ contains the appropriate amount of XELJANZ as a citrate salt and the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, HPMC 2910/Hypromellose 6cP, titanium dioxide, macrogol/PEG3350, and triacetin.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Tofacitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Tofacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through pairing of JAKs (e.g., JAK1/JAK3, JAK1/JAK2, JAK1/TyK2, JAK2/JAK2). Tofacitinib inhibited the <span class="Italics">in vitro</span> activities of JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 combinations with IC<span class="Sub">50</span> of 406, 56, and 1377 nM, respectively. However, the relevance of specific JAK combinations to therapeutic effectiveness is not known.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Treatment with XELJANZ was associated with dose-dependent reductions of circulating CD16/56+ natural killer cells, with estimated maximum reductions occurring at approximately 8–10 weeks after initiation of therapy. These changes generally resolved within 2–6 weeks after discontinuation of treatment. Treatment with XELJANZ was associated with dose-dependent increases in B cell counts. Changes in circulating T-lymphocyte counts and T-lymphocyte subsets (CD3+, CD4+ and CD8+) were small and inconsistent. The clinical significance of these changes is unknown.</p>
<p>Total serum IgG, IgM, and IgA levels after 6-month dosing in patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> were lower than placebo; however, changes were small and not dose-dependent.</p>
<p>After treatment with XELJANZ in patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, rapid decreases in serum C-reactive protein (CRP) were observed and maintained throughout dosing. Changes in CRP observed with XELJANZ treatment do not reverse fully within 2 weeks after discontinuation, indicating a longer duration of pharmacodynamic activity compared to the pharmacokinetic half-life.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Following oral administration of XELJANZ, peak plasma concentrations are reached within 0.5–1 hour, elimination half-life is ~3 hours and a dose-proportional increase in systemic exposure was observed in the therapeutic dose range. Steady state concentrations are achieved in 24–48 hours with negligible accumulation after twice daily administration.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold">Absorption</span></p>
<p>The absolute oral bioavailability of tofacitinib is 74%. Coadministration of XELJANZ with a high-fat meal resulted in no changes in AUC while C<span class="Sub">max</span> was reduced by 32%. In clinical trials, XELJANZ was administered without regard to meals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold">Distribution</span></p>
<p>After intravenous administration, the volume of distribution is 87 L. The protein binding of tofacitinib is ~40%. Tofacitinib binds predominantly to albumin and does not appear to bind to α1-acid glycoprotein. Tofacitinib distributes equally between red blood cells and plasma.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold">Metabolism and Elimination</span></p>
<p>Clearance mechanisms for tofacitinib are approximately 70% hepatic metabolism and 30% renal excretion of the parent drug. The metabolism of tofacitinib is primarily mediated by CYP3A4 with minor contribution from CYP2C19. In a human radiolabeled study, more than 65% of the total circulating radioactivity was accounted for by unchanged tofacitinib, with the remaining 35% attributed to 8 metabolites, each accounting for less than 8% of total radioactivity. The pharmacologic activity of tofacitinib is attributed to the parent molecule.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold">Pharmacokinetics in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span> Patients</span></p>
<p>Population PK analysis in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients indicated no clinically relevant change in tofacitinib exposure, after accounting for differences in renal function (i.e., creatinine clearance) between patients, based on age, weight, gender and race (Figure 1). An approximately linear relationship between body weight and volume of distribution was observed, resulting in higher peak (C<span class="Sub">max</span>) and lower trough (C<span class="Sub">min</span>) concentrations in lighter patients. However, this difference is not considered to be clinically relevant. The between-subject variability (% coefficient of variation) in AUC of tofacitinib is estimated to be approximately 27%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold">Specific Populations</span></p>
<p>The effect of renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and other intrinsic factors on the pharmacokinetics of tofacitinib is shown in Figure 1.</p>
<p><span class="Bold">Figure 1: Impact of Intrinsic Factors on Tofacitinib Pharmacokinetics</span></p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13&amp;name=xeljanz-02.jpg"></div>
<p>Reference values for weight, age, gender, and race comparisons are 70 kg, 55 years, male, and White, respectively; Reference groups for renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> data are subjects with normal renal and hepatic function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.1"></a><p></p>
<p class="First"><span class="Bold">Potential for XELJANZ to Influence the PK of Other Drugs</span></p>
<p><span class="Italics">In vitro</span> studies indicate that tofacitinib does not significantly inhibit or induce the activity of the major human drug-metabolizing CYPs (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) at concentrations exceeding 185 times the steady state C<span class="Sub">max</span> of a 5 mg twice daily dose. These <span class="Italics">in vitro</span> results were confirmed by a human drug interaction study showing no changes in the PK of midazolam, a highly sensitive CYP3A4 substrate, when coadministered with XELJANZ.</p>
<p>In <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients, the oral clearance of tofacitinib does not vary with time, indicating that tofacitinib does not normalize CYP enzyme activity in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients. Therefore, coadministration with XELJANZ is not expected to result in clinically relevant increases in the metabolism of CYP substrates in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients.</p>
<p><span class="Italics">In vitro</span> data indicate that the potential for tofacitinib to inhibit transporters such as P-glycoprotein, organic anionic or cationic transporters at therapeutic concentrations is low.</p>
<p>Dosing recommendations for coadministered drugs following administration with XELJANZ are shown in Figure 2.</p>
<p><span class="Bold">Figure 2. Impact of XELJANZ on PK of Other Drugs</span></p>
<div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13&amp;name=xeljanz-03.jpg"></div>
<p>Note: Reference group is administration of concomitant medication alone; OCT = Organic Cationic Transporter; MATE = Multidrug and Toxic Compound Extrusion</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.2"></a><p></p>
<p class="First"><span class="Bold">Potential for Other Drugs to Influence the PK of Tofacitinib</span></p>
<p>Since tofacitinib is metabolized by CYP3A4, interaction with drugs that inhibit or induce CYP3A4 is likely. Inhibitors of CYP2C19 alone or P-glycoprotein are unlikely to substantially alter the PK of tofacitinib. Dosing recommendations for XELJANZ for administration with CYP inhibitors or inducers are shown in Figure 3.</p>
<p><a name="fig3"></a><span class="Bold">Figure 3. Impact of Other Drugs on PK of XELJANZ</span></p>
<div class="Figure"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13&amp;name=xeljanz-04.jpg"></div>
<p>Note: Reference group is administration of tofacitinib alone</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 39-week toxicology study in monkeys, tofacitinib at exposure levels approximately 6 times the MRHD (on an AUC basis at oral doses of 5 mg/kg twice daily) produced <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>. No <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> were observed in this study at exposure levels 1 times the MRHD (on an AUC basis at oral doses of 1 mg/kg twice daily).</p>
<p>The carcinogenic potential of tofacitinib was assessed in 6-month rasH2 transgenic mouse carcinogenicity and 2-year rat carcinogenicity studies. Tofacitinib, at exposure levels approximately 34 times the MRHD (on an AUC basis at oral doses of 200 mg/kg/day) was not carcinogenic in mice.</p>
<p>In the 24-month oral carcinogenicity study in Sprague-Dawley rats, tofacitinib caused benign Leydig cell tumors, hibernomas (malignancy of brown adipose tissue), and benign thymomas at doses greater than or equal to 30 mg/kg/day (approximately 42 times the exposure levels at the MRHD on an AUC basis). The relevance of benign Leydig cell tumors to human risk is not known.</p>
<p>Tofacitinib was not mutagenic in the bacterial reverse mutation assay. It was positive for clastogenicity in the <span class="Italics">in vitro</span> chromosome aberration assay with human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> in the presence of metabolic enzymes, but negative in the absence of metabolic enzymes. Tofacitinib was negative in the <span class="Italics">in vivo</span> rat micronucleus assay and in the <span class="Italics">in vitro</span> CHO-HGPRT assay and the <span class="Italics">in vivo</span> rat hepatocyte unscheduled DNA synthesis assay.</p>
<p>In rats, tofacitinib at exposure levels approximately 17 times the MRHD (on an AUC basis at oral doses of 10 mg/kg/day) reduced female fertility due to increased post-implantation loss. There was no impairment of female rat fertility at exposure levels of tofacitinib equal to the MRHD (on an AUC basis at oral doses of 1 mg/kg/day). Tofacitinib exposure levels at approximately 133 times the MRHD (on an AUC basis at oral doses of 100 mg/kg/day) had no effect on male fertility, sperm motility, or sperm concentration.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The XELJANZ clinical development program included two dose-ranging trials and five confirmatory trials.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold">DOSE-RANGING TRIALS</span></p>
<p>Dose selection for XELJANZ was based on two pivotal dose-ranging trials.</p>
<p>Dose-Ranging Study 1 was a 6-month monotherapy trial in 384 patients with active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> who had an inadequate response to a DMARD. Patients who previously received adalimumab therapy were excluded. Patients were randomized to 1 of 7 monotherapy treatments: XELJANZ 1, 3, 5, 10 or 15 mg twice daily, adalimumab 40 mg subcutaneously every other week for 10 weeks followed by XELJANZ 5 mg twice daily for 3 months, or placebo.</p>
<p>Dose-Ranging Study 2 was a 6-month trial in which 507 patients with active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> who had an inadequate response to MTX alone received one of 6 dose regimens of XELJANZ (20 mg once daily; 1, 3, 5, 10 or 15 mg twice daily), or placebo added to background MTX.</p>
<p>The results of XELJANZ-treated patients achieving ACR20 responses in Studies 1 and 2 are shown in Figure 4. Although a dose-response relationship was observed in Study 1, the proportion of patients with an ACR20 response did not clearly differ between the 10 mg and 15 mg doses. Furthermore, there was a smaller proportion of patients who responded to adalimumab monotherapy compared to those treated with XELJANZ doses 3 mg twice daily and greater. In Study 2, a smaller proportion of patients achieved an ACR20 response in the placebo and XELJANZ 1 mg groups compared to patients treated with the other XELJANZ doses. However, there was no difference in the proportion of responders among patients treated with XELJANZ 3, 5, 10, 15 mg twice daily or 20 mg once daily doses.</p>
<p><span class="Bold">Figure 4: Proportion of Patients with ACR20 Response at Month 3 in Dose-Ranging Studies 1 and 2</span></p>
<div class="Figure"><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13&amp;name=xeljanz-05.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<p class="First"><span class="Bold">CONFIRMATORY TRIALS</span></p>
<p>Study I was a 6-month monotherapy trial in which 610 patients with moderate to severe active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> who had an inadequate response to a DMARD (nonbiologic or biologic) received XELJANZ 5 or 10 mg twice daily or placebo. At the Month 3 visit, all patients randomized to placebo treatment were advanced in a blinded fashion to a second predetermined treatment of XELJANZ 5 or 10 mg twice daily. The primary endpoints at Month 3 were the proportion of patients who achieved an ACR20 response, changes in Health Assessment Questionnaire – <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> Index (HAQ-DI), and rates of Disease Activity Score DAS28-4(ESR) less than 2.6.</p>
<p>Study II was a 12-month trial in which 792 patients with moderate to severe active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> who had an inadequate response to a nonbiologic DMARD received XELJANZ 5 or 10 mg twice daily or placebo added to background DMARD treatment (excluding potent immunosuppressive treatments such as azathioprine or cyclosporine). At the Month 3 visit, nonresponding patients were advanced in a blinded fashion to a second predetermined treatment of XELJANZ 5 or 10 mg twice daily. At the end of Month 6, all placebo patients were advanced to their second predetermined treatment in a blinded fashion. The primary endpoints were the proportion of patients who achieved an ACR20 response at Month 6, changes in HAQ-DI at Month 3, and rates of DAS28-4(ESR) less than 2.6 at Month 6.</p>
<p>Study III was a 12-month trial in 717 patients with moderate to severe active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> who had an inadequate response to MTX. Patients received XELJANZ 5 or 10 mg twice daily, adalimumab 40 mg subcutaneously every other week, or placebo added to background MTX.</p>
<p>Placebo patients were advanced as in Study II. The primary endpoints were the proportion of patients who achieved an ACR20 response at Month 6, HAQ-DI at Month 3, and DAS28-4(ESR) less than 2.6 at Month 6.</p>
<p>Study IV is an ongoing 2-year trial with a planned analysis at 1 year in which 797 patients with moderate to severe active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> who had an inadequate response to MTX received XELJANZ 5 or 10 mg twice daily or placebo added to background MTX. Placebo patients were advanced as in Study II. The primary endpoints were the proportion of patients who achieved an ACR20 response at Month 6, mean change from baseline in van der Heijde-modified total Sharp Score (mTSS) at Month 6, HAQ-DI at Month 3, and DAS28-4(ESR) less than 2.6 at Month 6.</p>
<p>Study V was a 6-month trial in which 399 patients with moderate to severe active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> who had an inadequate response to at least one approved TNF-inhibiting biologic agent received XELJANZ 5 or 10 mg twice daily or placebo added to background MTX. At the Month 3 visit, all patients randomized to placebo treatment were advanced in a blinded fashion to a second predetermined treatment of XELJANZ 5 or 10 mg twice daily. The primary endpoints at Month 3 were the proportion of patients who achieved an ACR20 response, HAQ-DI, and DAS28-4(ESR) less than 2.6.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2.1"></a><p></p>
<p class="First"><span class="Bold">Clinical Response</span></p>
<p>The percentages of XELJANZ-treated patients achieving ACR20, ACR50, and ACR70 responses in Studies I, IV, and V are shown in Table 5. Similar results were observed with Studies II and III. In all trials, patients treated with either 5 or 10 mg twice daily XELJANZ had higher ACR20, ACR50, and ACR70 response rates versus placebo, with or without background DMARD treatment, at Month 3 and Month 6. Higher ACR20 response rates were observed within 2 weeks compared to placebo. In the 12-month trials, ACR response rates in XELJANZ-treated patients were consistent at 6 and 12 months.</p>
<table width="100%">
<caption><span>Table 5: Proportion of Patients with an ACR Response</span></caption>
<col align="left" valign="top" width="10%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="11%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="9">Percent of Patients</th>
</tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="3">Monotherapy in Nonbiologic or Biologic DMARD Inadequate Responders<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Lrule Rrule" align="center" colspan="3">MTX Inadequate Responders<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</th>
<th class="Rrule" align="center" colspan="3">TNF Inhibitor Inadequate Responders<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</th>
</tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="3">Study I</th>
<th class="Rrule" align="center" colspan="3">Study IV</th>
<th class="Rrule" align="center" colspan="3">Study V</th>
</tr>
<tr>
<th class="Lrule" align="left">N<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</th>
<th class="Lrule Rrule" align="center">PBO</th>
<th class="Rrule" align="center">XELJANZ<br>5 mg Twice Daily</th>
<th class="Rrule" align="center">XELJANZ 10 mg Twice Daily</th>
<th class="Rrule" align="center">PBO<br>+ MTX</th>
<th class="Rrule" align="center">XELJANZ<br>5 mg Twice Daily + MTX</th>
<th class="Rrule" align="center">XELJANZ<br>10 mg Twice Daily + MTX</th>
<th class="Rrule" align="center">PBO + MTX</th>
<th class="Rrule" align="center">XELJANZ<br>5 mg Twice Daily + MTX</th>
<th class="Rrule" align="center">XELJANZ<br>10 mg Twice Daily + MTX</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">122</th>
<th class="Rrule" align="center">243</th>
<th class="Rrule" align="center">245</th>
<th class="Rrule" align="center">160</th>
<th class="Rrule" align="center">321</th>
<th class="Rrule" align="center">316</th>
<th class="Rrule" align="center">132</th>
<th class="Rrule" align="center">133</th>
<th class="Rrule" align="center">134</th>
</tr>
</thead>
<tfoot><tr><td colspan="10" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Inadequate response to at least one DMARD (biologic or nonbiologic) due to lack of efficacy or toxicity.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Inadequate response to MTX defined as the presence of sufficient residual disease activity to meet the entry criteria.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Inadequate response to a least one TNF inhibitor due to lack of efficacy and/or intolerance.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>N is number of randomized and treated patients.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd>NA Not applicable, as data for placebo treatment is not available beyond 3 months in Studies I and V due to placebo advancement.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">ACR20</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Month 3</td>
<td class="Rrule" align="center">26%</td>
<td class="Rrule" align="center">59%</td>
<td class="Rrule" align="center">65%</td>
<td class="Rrule" align="center">27%</td>
<td class="Rrule" align="center">55%</td>
<td class="Rrule" align="center">67%</td>
<td class="Rrule" align="center">24%</td>
<td class="Rrule" align="center">41%</td>
<td class="Rrule" align="center">48%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Month 6</td>
<td class="Rrule" align="center">NA<a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">69%</td>
<td class="Rrule" align="center">70%</td>
<td class="Rrule" align="center">25%</td>
<td class="Rrule" align="center">50%</td>
<td class="Rrule" align="center">62%</td>
<td class="Rrule" align="center">NA</td>
<td class="Rrule" align="center">51%</td>
<td class="Rrule" align="center">54%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">ACR50</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Month 3</td>
<td class="Rrule" align="center">12%</td>
<td class="Rrule" align="center">31%</td>
<td class="Rrule" align="center">36%</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">29%</td>
<td class="Rrule" align="center">37%</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">26%</td>
<td class="Rrule" align="center">28%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Month 6</td>
<td class="Rrule" align="center">NA</td>
<td class="Rrule" align="center">42%</td>
<td class="Rrule" align="center">46%</td>
<td class="Rrule" align="center">9%</td>
<td class="Rrule" align="center">32%</td>
<td class="Rrule" align="center">44%</td>
<td class="Rrule" align="center">NA</td>
<td class="Rrule" align="center">37%</td>
<td class="Rrule" align="center">30%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">ACR70</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Month 3</td>
<td class="Rrule" align="center">6%</td>
<td class="Rrule" align="center">15%</td>
<td class="Rrule" align="center">20%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">11%</td>
<td class="Rrule" align="center">17%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">14%</td>
<td class="Rrule" align="center">10%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Month 6</td>
<td class="Rrule" align="center">NA</td>
<td class="Rrule" align="center">22%</td>
<td class="Rrule" align="center">29%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">14%</td>
<td class="Rrule" align="center">23%</td>
<td class="Rrule" align="center">NA</td>
<td class="Rrule" align="center">16%</td>
<td class="Rrule" align="center">16%</td>
</tr>
</tbody>
</table>
<p>In Study IV, a greater proportion of patients treated with XELJANZ 5 mg or 10 mg twice daily plus MTX achieved a low level of disease activity as measured by a DAS28-4(ESR) less than 2.6 at 6 months compared to those treated with MTX alone (Table 6).</p>
<table width="100%">
<caption><span>Table 6: Proportion of Patients with DAS28-4(ESR) Less Than 2.6 with Number of Residual Active Joints</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="22%">
<col align="center" valign="top" width="22%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="left" colspan="4">Study IV</th></tr>
<tr>
<th class="Lrule Rrule" align="left">DAS28-4(ESR) Less Than 2.6</th>
<th class="Rrule" align="center">Placebo + MTX</th>
<th class="Rrule" align="center">XELJANZ 5 mg Twice Daily + MTX</th>
<th class="Rrule" align="center">XELJANZ 10 mg Twice Daily + MTX</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">160</th>
<th class="Rrule" align="center">321</th>
<th class="Rrule" align="center">316</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Proportion of responders at Month 6 (n)</td>
<td class="Rrule" align="center">1% (2)</td>
<td class="Rrule" align="center">6% (19)</td>
<td class="Rrule" align="center">13% (42)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Of responders, proportion with 0 active joints (n)</td>
<td class="Rrule" align="center">50% (1)</td>
<td class="Rrule" align="center">42% (8)</td>
<td class="Rrule" align="center">36% (15)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Of responders, proportion with 1 active joint (n)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5% (1)</td>
<td class="Rrule" align="center">17% (7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Of responders, proportion with 2 active joints (n)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">32% (6)</td>
<td class="Rrule" align="center">7% (3)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Of responders, proportion with 3 or more active joints (n)</td>
<td class="Rrule" align="center">50% (1)</td>
<td class="Rrule" align="center">21% (4)</td>
<td class="Rrule" align="center">40% (17)</td>
</tr>
</tbody>
</table>
<p>The results of the components of the ACR response criteria for Study IV are shown in Table 7. Similar results were observed in Studies I, II, III, and V.</p>
<table width="100%">
<caption><span>Table 7: Components of ACR Response at 3 Months</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="12%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="6">Study IV</th>
</tr>
<tr>
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">XELJANZ<br>5 mg<br>Twice Daily + MTX</th>
<th class="Rrule" align="center" colspan="2">XELJANZ<br>10 mg<br>Twice Daily + MTX</th>
<th class="Rrule" align="center" colspan="2">Placebo + MTX</th>
</tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">N=321</th>
<th class="Rrule" align="center" colspan="2">N=316</th>
<th class="Rrule" align="center" colspan="2">N=160</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Component (mean) <a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Baseline</th>
<th class="Rrule" align="center">Month 3<a href="#footnote-6" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Baseline</th>
<th class="Rrule" align="center">Month 3<a href="#footnote-6" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Baseline</th>
<th class="Rrule" align="center">Month 3<a href="#footnote-6" class="Sup">*</a>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Data shown is mean (Standard Deviation) at Month 3.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>Visual analog scale: 0 = best, 100 = worst.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>Health Assessment Questionnaire <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> Index: 0 = best, 3 = worst; 20 questions; categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Number of tender joints<br>(0–68)</td>
<td class="Rrule" align="center" valign="middle">24<br>(14)</td>
<td class="Rrule" align="center" valign="middle">13<br>(14)</td>
<td class="Rrule" align="center" valign="middle">23<br>(15)</td>
<td class="Rrule" align="center" valign="middle">10<br>(12)</td>
<td class="Rrule" align="center" valign="middle">23<br>(13)</td>
<td class="Rrule" align="center" valign="middle">18<br>(14)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Number of <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">swollen joints</span><br>(0–66)</td>
<td class="Rrule" align="center" valign="middle">14<br>(8)</td>
<td class="Rrule" align="center" valign="middle">6<br>(8)</td>
<td class="Rrule" align="center" valign="middle">14<br>(8)</td>
<td class="Rrule" align="center" valign="middle">6<br>(7)</td>
<td class="Rrule" align="center" valign="middle">14<br>(9)</td>
<td class="Rrule" align="center" valign="middle">10<br>(9)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a>
</td>
<td class="Rrule" align="center" valign="middle">58<br>(23)</td>
<td class="Rrule" align="center" valign="middle">34<br>(23)</td>
<td class="Rrule" align="center" valign="middle">58<br>(24)</td>
<td class="Rrule" align="center" valign="middle">29<br>(22)</td>
<td class="Rrule" align="center" valign="middle">55<br>(24)</td>
<td class="Rrule" align="center" valign="middle">47<br>(24)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Patient global assessment<a href="#footnote-7" class="Sup">†</a>
</td>
<td class="Rrule" align="center" valign="middle">58<br>(24)</td>
<td class="Rrule" align="center" valign="middle">35<br>(23)</td>
<td class="Rrule" align="center" valign="middle">57<br>(23)</td>
<td class="Rrule" align="center" valign="middle">29<br>(20)</td>
<td class="Rrule" align="center" valign="middle">54<br>(23)</td>
<td class="Rrule" align="center" valign="middle">47<br>(24)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">Disability</span> index<br>(HAQ-DI)<a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a>
</td>
<td class="Rrule" align="center" valign="middle">1.41<br>(0.68)</td>
<td class="Rrule" align="center" valign="middle">0.99<br>(0.65)</td>
<td class="Rrule" align="center" valign="middle">1.40<br>(0.66)</td>
<td class="Rrule" align="center" valign="middle">0.84<br>(0.64)</td>
<td class="Rrule" align="center" valign="middle">1.32<br>(0.67)</td>
<td class="Rrule" align="center" valign="middle">1.19<br>(0.68)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Physician global assessment<a href="#footnote-7" class="Sup">†</a>
</td>
<td class="Rrule" align="center" valign="middle">59<br>(16)</td>
<td class="Rrule" align="center" valign="middle">30<br>(19)</td>
<td class="Rrule" align="center" valign="middle">58<br>(17)</td>
<td class="Rrule" align="center" valign="middle">24<br>(17)</td>
<td class="Rrule" align="center" valign="middle">56<br>(18)</td>
<td class="Rrule" align="center" valign="middle">43<br>(22)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">CRP (mg/L)</td>
<td class="Rrule" align="center" valign="middle">15.3<br>(19.0)</td>
<td class="Rrule" align="center" valign="middle">7.1<br>(19.1)</td>
<td class="Rrule" align="center" valign="middle">17.1<br>(26.9)</td>
<td class="Rrule" align="center" valign="middle">4.4<br>(8.6)</td>
<td class="Rrule" align="center" valign="middle">13.7<br>(14.9)</td>
<td class="Rrule" align="center" valign="middle">14.6<br>(18.7)</td>
</tr>
</tbody>
</table>
<p>The percent of ACR20 responders by visit for Study IV is shown in Figure 5. Similar responses were observed in Studies I, II, III and V.</p>
<p><span class="Bold">Figure 5: Percentage of ACR20 Responders by Visit for Study IV</span></p>
<div class="Figure"><img alt="Figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13&amp;name=xeljanz-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2.2"></a><p></p>
<p class="First"><span class="Bold">Physical Function Response</span></p>
<p>Improvement in physical functioning was measured by the HAQ-DI. Patients receiving XELJANZ 5 and 10 mg twice daily demonstrated greater improvement from baseline in physical functioning compared to placebo at Month 3.</p>
<p>The mean (95% CI) difference from placebo in HAQ-DI improvement from baseline at Month 3 in Study III was -0.22 (-0.35, -0.10) in patients receiving 5 mg XELJANZ twice daily and -0.32 (-0.44, -0.19) in patients receiving 10 mg XELJANZ twice daily. Similar results were obtained in Studies I, II, IV and V. In the 12-month trials, HAQ-DI results in XELJANZ-treated patients were consistent at 6 and 12 months.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">XELJANZ is provided as 5 mg tofacitinib (equivalent to 8 mg tofacitinib citrate) tablets: White, round, immediate-release film-coated tablets, debossed with "Pfizer" on one side, and "JKI 5" on the other side, and available in:</p>
<table class="Noautorules" width="50%">
<col align="left" valign="top" width="50%">
<col align="right" valign="top" width="50%">
<tbody class="Headless">
<tr>
<td align="left">Bottles of 60:</td>
<td align="right">NDC 0069-1001-01</td>
</tr>
<tr>
<td align="left">Bottles of 180:</td>
<td align="right">NDC 0069-1001-02</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage and Handling</span></p>
<p>Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature].</p>
<p>Do not repackage.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (<a href="#mg">Medication Guide</a>).</p>
<p>Inform patients of the availability of a Medication Guide, and instruct them to read the Medication Guide prior to taking XELJANZ. Instruct patients to take XELJANZ only as prescribed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com.</p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13&amp;name=xeljanz-07.jpg"></p>
<p>LAB-0445-1.0</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="mg"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">XELJANZ (ZEL' JANS')<br>(tofacitinib)</span></p>
<p>Read this Medication Guide before you start taking XELJANZ and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment.</p>
<p><a name="important"></a><span class="Bold">What is the most important information I should know about XELJANZ?</span></p>
<p><span class="Bold">XELJANZ may cause serious side effects including:</span></p>
<p><span class="Bold">1. Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</span></p>
<p>XELJANZ is a medicine that affects your immune system. XELJANZ can lower the ability of your immune system to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Some people have serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> while taking XELJANZ, including <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> (TB), and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<ul class="Disc">
<li>Your healthcare provider should test you for TB before starting XELJANZ.</li>
<li>Your healthcare provider should monitor you closely for signs and symptoms of TB <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> during treatment with XELJANZ.</li>
</ul>
<p>You should not start taking XELJANZ if you have any kind of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> unless your healthcare provider tells you it is okay.</p>
<p>Before starting XELJANZ, tell your healthcare provider if you:</p>
<ul class="Disc">
<li>think you have an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or have symptoms of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> such as:<table class="Noautorules" width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span></li>
<li><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
<li>blood in <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">phlegm</span></li>
<li><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></li>
</ul></td>
<td align="left"><ul class="Circle">
<li>warm, red, or painful skin or sores on your body</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>burning when you urinate or urinating more often than normal</li>
<li>feeling very tired</li>
</ul></td>
</tr></tbody>
</table>
</li>
<li>are being treated for an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></li>
<li>get a lot of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or have <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that keep coming back</li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, HIV, or a weak immune system. People with these conditions have a higher chance for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</li>
<li>have TB, or have been in close contact with someone with TB</li>
<li>live or have lived, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> (<span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span>, <span class="product-label-link" type="condition" conceptid="437217" conceptname="Coccidioidomycosis">coccidioidomycosis</span>, or <span class="product-label-link" type="condition" conceptid="433146" conceptname="Blastomycosis">blastomycosis</span>). These <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may happen or become more severe if you use XELJANZ. Ask your healthcare provider if you do not know if you have lived in an area where these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> are common.</li>
<li>have or have had <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C</li>
</ul>
<p>After starting XELJANZ, call your healthcare provider right away if you have any symptoms of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. XELJANZ can make you more likely to get <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or make worse any <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> that you have.</p>
<p><span class="Bold">2. Cancer and immune system problems.</span></p>
<p>XELJANZ may increase your risk of certain cancers by changing the way your immune system works.</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and other cancers can happen in patients taking XELJANZ. Tell your healthcare provider if you have ever had any type of cancer.</li>
<li>Some people who have taken XELJANZ with certain other medicines to prevent kidney <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">transplant rejection</span> have had a problem with certain white blood cells growing out of control (Epstein Barr Virus-associated <span class="product-label-link" type="condition" conceptid="42872948" conceptname="Post transplant lymphoproliferative disorder">post transplant lymphoproliferative disorder</span>).</li>
</ul>
<p><span class="Bold">3. Tears (perforation) in the stomach or intestines.</span></p>
<ul class="Disc">
<li>Tell your healthcare provider if you have had <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span> (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in parts of the large intestine) or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in your stomach or intestines. Some people taking XELJANZ get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate.</li>
<li>Tell your healthcare provider right away if you have <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and stomach-area <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> that does not go away, and a change in your bowel habits.</li>
</ul>
<p><span class="Bold">4. Changes in certain laboratory test results.</span> Your healthcare provider should do blood tests before you start receiving XELJANZ and while you take XELJANZ to check for the following side effects:</p>
<ul class="Disc">
<li>
<span class="Bold">changes in lymphocyte counts.</span> <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">Lymphocytes</span> are white blood cells that help the body fight off <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</li>
<li>
<span class="Bold">low neutrophil counts</span>. <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> are white blood cells that help the body fight off <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</li>
<li>
<span class="Bold">low red blood cell count</span>. This may mean that you have <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, which may make you feel weak and tired.</li>
</ul>
<p>Your healthcare provider should routinely check certain liver tests.</p>
<p>You should not receive XELJANZ if your lymphocyte count, neutrophil count, or red blood cell count is too low or your liver tests are too high.</p>
<p>Your healthcare provider may stop your XELJANZ treatment for a period of time if needed because of changes in these blood test results.</p>
<p>You may also have changes in other laboratory tests, such as your blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels<span class="Italics">.</span> Your healthcare provider should do blood tests to check your <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels 4 to 8 weeks after you start receiving XELJANZ, and as needed after that. Normal <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels are important to good heart health.</p>
<p>See "<a href="#sideeffects">What are the possible side effects of XELJANZ?</a>" for more information about side effects.</p>
<p><span class="Bold">What is XELJANZ?</span></p>
<p>XELJANZ is a prescription medicine called a Janus kinase (JAK) inhibitor. XELJANZ is used to treat adults with moderately to severely active <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> in which methotrexate did not work well.</p>
<p>It is not known if XELJANZ is safe and effective in people with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B or C.</p>
<p>XELJANZ is not for people with severe liver problems.</p>
<p>It is not known if XELJANZ is safe and effective in children.</p>
<p><span class="Bold">What should I tell my healthcare provider before taking XELJANZ?</span></p>
<p><span class="Bold">XELJANZ may not be right for you. Before taking XELJANZ, tell your healthcare provider if you:</span></p>
<ul class="Disc">
<li>have an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. See "<a href="#important">What is the most important information I should know about XELJANZ?</a>"</li>
<li>have liver problems</li>
<li>have kidney problems</li>
<li>have any stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or been diagnosed with <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span> or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in your stomach or intestines</li>
<li>have had a reaction to tofacitinib or any of the ingredients in XELJANZ</li>
<li>have recently received or are scheduled to receive a vaccine. People who take XELJANZ should not receive live vaccines. People taking XELJANZ can receive non-live vaccines.</li>
<li>have any other medical conditions</li>
<li>plan to become pregnant or are pregnant. It is not known if XELJANZ will harm an unborn baby.<p class="First">Pregnancy Registry: Pfizer has a registry for pregnant women who take XELJANZ. The purpose of this registry is to check the health of the pregnant mother and her baby. If you are pregnant or become pregnant while taking XELJANZ, talk to your healthcare provider about how you can join this pregnancy registry or you may contact the registry at 1-877-311-8972 to enroll.</p>
</li>
<li>plan to breastfeed or are breastfeeding. You and your healthcare provider should decide if you will take XELJANZ or breastfeed. You should not do both.</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and non-prescription medicines, vitamins, and herbal supplements. XELJANZ and other medicines may affect each other causing side effects.</p>
<p>Especially tell your healthcare provider if you take:</p>
<ul class="Disc">
<li>any other medicines to treat your <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>. You should not take tocilizumab (Actemra<span class="Sup">®</span>), etanercept (Enbrel<span class="Sup">®</span>), adalimumab (Humira<span class="Sup">®</span>), infliximab (Remicade<span class="Sup">®</span>), rituximab (Rituxan<span class="Sup">®</span>), abatacept (Orencia<span class="Sup">®</span>), anakinra (Kineret<span class="Sup">®</span>), certolizumab (Cimzia<span class="Sup">®</span>), golimumab (Simponi<span class="Sup">®</span>), azathioprine, cyclosporine, or other immunosuppressive drugs while you are taking XELJANZ. Taking XELJANZ with these medicines may increase your risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
<li>medicines that affect the way certain liver enzymes work. Ask your healthcare provider if you are not sure if your medicine is one of these.</li>
</ul>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take XELJANZ?</span></p>
<ul class="Disc">
<li>Take XELJANZ as your healthcare provider tells you to take it.</li>
<li>Take XELJANZ 2 times a day with or without food.</li>
<li>If you take too much XELJANZ, call your healthcare provider or go to the nearest hospital emergency room right away.</li>
</ul>
<p><a name="sideeffects"></a><span class="Bold">What are possible side effects of XELJANZ?</span></p>
<p><span class="Bold">XELJANZ may cause serious side effects, including:</span></p>
<ul class="Disc">
<li>See "<a href="#important">What is the most important information I should know about XELJANZ?</a>"</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B or C activation <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span> in people who carry the virus in their blood. If you are a carrier of the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C virus (viruses that affect the liver), the virus may become active while you use XELJANZ. Your healthcare provider may do blood tests before you start treatment with XELJANZ and while you are using XELJANZ. Tell your healthcare provider if you have any of the following symptoms of a possible <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>:<table class="Noautorules" width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Circle">
<li>feel very tired</li>
<li>skin or eyes look yellow</li>
<li>little or no appetite</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>clay-colored bowel movements</li>
</ul></td>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fevers</span></li>
<li><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></li>
<li><span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span></li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span></li>
<li>dark urine</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span></li>
</ul></td>
</tr></tbody>
</table>
</li>
</ul>
<p>Common side effects of XELJANZ include:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span> (<span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinus infections</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, and <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span> (<span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>)</li>
</ul>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of XELJANZ. For more information, ask your healthcare provider or pharmacist.</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p><span class="Bold">You may also report side effects to Pfizer at 1-800-438-1985.</span></p>
<p><span class="Bold">How should I store XELJANZ?</span></p>
<p>Store XELJANZ at 68°F to 77°F (room temperature).</p>
<p>Safely throw away medicine that is out of date or no longer needed.</p>
<p><span class="Bold">Keep XELJANZ and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of XELJANZ.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use XELJANZ for a condition for which it was not prescribed. Do not give XELJANZ to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about XELJANZ. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about XELJANZ that is written for health professionals.</p>
<p><span class="Bold">What are the ingredients in XELJANZ?</span></p>
<p><span class="Bold">Active ingredient:</span> tofacitinib citrate</p>
<p><span class="Bold">Inactive ingredients:</span> microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, HPMC 2910/Hypromellose 6cP, titanium dioxide, macrogol/PEG3350, and triacetin.</p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13&amp;name=xeljanz-07.jpg"></p>
<p>LAB-0535-1.0<br>November 2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 60 Tablet Bottle Label</span></p>
<p><span class="Bold Italics">PROFESSIONAL SAMPLE-NOT FOR SALE<br>ALWAYS DISPENSE WITH MEDICATION GUIDE</span></p>
<p><span class="Bold Italics">Pfizer</span></p>
<p>NDC 63539-012-02</p>
<p><span class="Bold">Xeljanz</span>™<br>(tofacitinib tablets)</p>
<p><span class="Bold">5 mg*</span></p>
<p>60 Tablets</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 60 Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13&amp;name=xeljanz-08.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>XELJANZ 		
					</strong><br><span class="contentTableReg">tofacitinib citrate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63539-012</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TOFACITINIB CITRATE</strong> (TOFACITINIB) </td>
<td class="formItem">TOFACITINIB</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PFIZER;JK15</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63539-012-02</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203214</td>
<td class="formItem">11/08/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>U.S. Pharmaceuticals
							(829076905)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Pharmaceuticals LLC</td>
<td class="formItem"></td>
<td class="formItem">829084552</td>
<td class="formItem">LABEL(63539-012), PACK(63539-012)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Manufacturing Deutschland GmbH (Betriebsstätte Freiburg)</td>
<td class="formItem"></td>
<td class="formItem">341970073</td>
<td class="formItem">ANALYSIS(63539-012), LABEL(63539-012), MANUFACTURE(63539-012), PACK(63539-012)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>93b77ffd-fbfd-401b-999d-382efc343b37</div>
<div>Set id: 68e3d6b2-7838-4d2d-a417-09d919b43e13</div>
<div>Version: 1</div>
<div>Effective Time: 20121107</div>
</div>
</div> <div class="DistributorName">U.S. Pharmaceuticals</div></p>
</body></html>
